市場調査レポート

商品コード

1139888

計算生物学市場：用途別、サービス別、最終用途別：世界の機会分析および産業予測、2021-2031年

Computational Biology Market By Application, By Services, By End Use : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年06月01日 | 発行: Allied Market Research

| ページ情報: 英文 269 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,456 541,140円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,769 903,310円

レポートPDFをご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 10,995 1,721,597円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.58円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の計算生物学市場は、2021年に54億9320万米ドル、2031年には314億7710万米ドルに達し、2022年から2031年までのCAGRは19.5％と予測されています。

計算生物学は学際的な応用科学であり、数学、理論、コンピューターシミュレーションモデルを使用して基礎生物学の概念を活用し、生物システム、構造、生命のプロセスを研究するものです。生物学は、生物学的システムの表現とシミュレーション、および実験データの解釈のために、しばしば非常に大規模な計算手法（アルゴリズムなど）を使用することを伴います。

未知タンパク質と既知タンパク質の配列や構造の類似性、タンパク質と他の分子との相互作用から、機能予測を行う。このような解析には長い時間がかかるため、計算生物学に対する需要が急速に高まっています。したがって、これらの解析は、標的タンパク質の構造の3次元モデルを構築するプロセスを導き、そのモデルを改良し、ランク付けし、互いに比較して、最終的に予測値を選択します。生化学、制御、遺伝学のパスウェイは高度に枝分かれし、インターリーブされており、また動的であるため、モデル化と解析に高度な計算手法を使用する必要があります。

COVID-19の大流行は、計算生物学市場に影響を与えています。COVID-19の蔓延を抑えるため、世界中の政府が国境ロック、監禁、厳しい社会的距離の取り方などの厳しい制限を実施しました。これらの措置は世界経済に大きな影響を与え、さまざまな産業に影響を及ぼしました。製薬会社やバイオテクノロジー企業は、世界各国の政府とともに、ワクチン開発の支援から医薬品のサプライチェーンの課題に対する計画まで、COVID-19の発生に対処するために取り組んでいます。現在、約115のワクチン候補と155の分子が研究開発パイプラインにあります。

さらに、COVID-19の発生により、高い死亡率、高い伝染率、臨床的に承認された医薬品やワクチンが不足していることが判明しました。この感染症に対する安全で効果的な治療法を見つけるために、ウイルスの発症メカニズムをより深く理解し、新しい治療法を提案する計算生物学は非常に重要な役割を担っています。そのため、コンピュータサイエンスの進歩により、医薬化学、薬理学、生物学、遺伝学、ウイルス学におけるインシリコ手法は、これらの分野における現代の研究に関連した課題をカバーしています。さらに、現在の世界の健康への警告のため、このような計算機技術は、コロナウイルスの緊急事態と戦うための革新的で的を射たアプローチを提供するための研究を加速することができます。したがって、計算生物学は、治療法を見つけるために医療科学分野を不可逆的に助け、製薬市場の成長を後押しするでしょう。

世界の計算生物学市場の成長は、ゲノミクス、エピゲノミクス、プロテオミクス、メタゲノミクスなど、タンパク質の構造や相互作用の理解を深めるための様々な分野で計算生物学のツールに対する需要が高まっていることが主な要因です。さらに、創薬のための研究開発活動の増加、予測モデルの需要の急増、ヒトゲノムプロジェクトなどの集団シーケンシングプロジェクトでの利用、政府からの資金提供なども、市場成長の要因となっています。

計算生物学において高度なアルゴリズムや統計モデルを適用して生物学的データを解析することにより、研究者は重要な洞察を得ることができ、それを新薬の発見に活用することができます。さらに、機械学習と人工知能の応用により、研究者は生体システムの理解を深め、新薬を発見し、病気を治す新しいタンパク質を設計し、遺伝暗号を理解して病気の予知に役立てることができるようになったのです。計算生物学分野の新興企業数社は、医薬品開発プロセスに貢献するソフトウェアプラットフォームを提供しています。これは、同市場の収益拡大に貢献すると期待されています。

さらに、計算生物学の受託研究機関からの需要の増加が、市場の成長を後押ししています。受託研究機関のサービスプロバイダーは、顧客と協力して、要件に応じてカスタマイズされた計画を策定します。例えば、バイオインフォマティクスCRO, Inc.は、世界中のバイオテクノロジー企業にバイオインフォマティクスサービスを提供する受託研究機関です。

計算生物学ソフトウェア/ツールは、データからより重要な洞察を得るためのカスタム分析パイプラインの構築に役立ち、またバルクおよび単一細胞のRNA配列からの遺伝子発現データをさらに分析し、重み付け遺伝子共発現ネットワーク分析（WGCNA）などのネットワーク分析を実行するために使用することができます。製薬、バイオテクノロジー、医療機器など様々な分野で、製品開発のために計算生物学が利用されています。したがって、これらの分野の急速な発展は、世界の計算生物学市場の成長に大きく寄与しています。

しかしながら、計算生物学では検出できないアレルギー反応や術後の合併症、政府の不利なシナリオ、機器の高い初期費用と維持費、標準化の欠如、熟練労働者の不足などが、世界市場の主要な阻害要因として作用しています。

世界の計算生物学市場は、用途、サービス、最終用途、地域に区分されます。用途別では、細胞・生体シミュレーション、創薬・疾患モデリング、前臨床薬物開発、臨床試験、人体シミュレーションソフトウェアに分類されます。

細胞・生体シミュレーションは、コンピュータ、ゲノミクス、計算プロテオミクス、ファーマコゲノミクス、その他に細分化されます。創薬・疾患モデリングは、ターゲット同定、ターゲットバリデーション、リードディスカバリー、リード最適化に分別されます。前臨床医薬品開発は、薬物動態学と薬力学にセグメンテーションされます。臨床試験は、第I相、第II相、第III相に細分化されます。

概要
- 市場規模・予測
細胞・生体シミュレーション
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
創薬・疾患モデリング
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
前臨床医薬品開発
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
臨床試験
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
人体シミュレーションソフトウェア
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章計算生物学市場：サービス別

概要
- 市場規模・予測
インハウス
- 主な市場動向、成長要因と機会
- 市場規模・予測：地域別
- 市場分析：国別
コントラクト
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章計算生物学市場：エンドユーザー別

概要
- 市場規模・予測
アカデミック＆リサーチ
- 主な市場動向、成長要因と機会
- 市場規模・予測：地域別
- 市場分析：国別分析
商業
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章計算生物学市場：地域別

概要
- 市場規模・予測
北米
- 主な動向と機会
- 北米の市場規模・予測：アプリケーション別
- 北米市場規模・予測：サービス別
- 北米市場の規模・予測：エンドユーザー別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州市場規模・予測：アプリケーション別
- 欧州市場規模・予測：サービス別
- 欧州市場規模・予測：エンドユーザー別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他の欧州地域
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：アプリケーション別
- アジア太平洋地域の市場規模・予測：サービス別
- アジア太平洋地域の市場規模・予測：エンドユーザー別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - オーストラリア
  - インド
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：アプリケーション別
- LAMEAの市場規模・予測：サービス別
- LAMEAの市場規模・予測：エンドユーザー別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

Chemical Computing Group Inc.
Compugen Ltd.
Simulation Plus Inc.
Genedata AG
Certara
Insilico Biotechnology AG
Accelrys
Rhenovia Pharma SAS
Entelos
Nimbus Discovery LLC
Rhenovia Pharma SAS & Leadscope Inc.

図表

LIST OF TABLES

TABLE 1. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 2. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CELLULAR & BIOLOGICAL SIMULATION, BY REGION , 2021-2031,($MILLION)
TABLE 3. COMPUTATIONAL BIOLOGY MARKET FOR CELLULAR & BIOLOGICAL SIMULATION BY COUNTRY, 2021-2031,($MILLION)
TABLE 4. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR DRUG DISCOVERY & DISEASE MODELLING, BY REGION , 2021-2031,($MILLION)
TABLE 5. COMPUTATIONAL BIOLOGY MARKET FOR DRUG DISCOVERY & DISEASE MODELLING BY COUNTRY, 2021-2031,($MILLION)
TABLE 6. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION , 2021-2031,($MILLION)
TABLE 7. COMPUTATIONAL BIOLOGY MARKET FOR PRECLINICAL DRUG DEVELOPMENT BY COUNTRY, 2021-2031,($MILLION)
TABLE 8. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CLINICAL TRIALS, BY REGION , 2021-2031,($MILLION)
TABLE 9. COMPUTATIONAL BIOLOGY MARKET FOR CLINICAL TRIALS BY COUNTRY, 2021-2031,($MILLION)
TABLE 10. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR HUMAN BODY SIMULATION SOFTWARE, BY REGION , 2021-2031,($MILLION)
TABLE 11. COMPUTATIONAL BIOLOGY MARKET FOR HUMAN BODY SIMULATION SOFTWARE BY COUNTRY, 2021-2031,($MILLION)
TABLE 12. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 13. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR IN-HOUSE, BY REGION , 2021-2031,($MILLION)
TABLE 14. COMPUTATIONAL BIOLOGY MARKET FOR IN-HOUSE BY COUNTRY, 2021-2031,($MILLION)
TABLE 15. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CONTRACT, BY REGION , 2021-2031,($MILLION)
TABLE 16. COMPUTATIONAL BIOLOGY MARKET FOR CONTRACT BY COUNTRY, 2021-2031,($MILLION)
TABLE 17. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 18. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR ACADEMICS & RESEARCH, BY REGION , 2021-2031,($MILLION)
TABLE 19. COMPUTATIONAL BIOLOGY MARKET FOR ACADEMICS & RESEARCH BY COUNTRY, 2021-2031,($MILLION)
TABLE 20. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR COMMERCIAL, BY REGION , 2021-2031,($MILLION)
TABLE 21. COMPUTATIONAL BIOLOGY MARKET FOR COMMERCIAL BY COUNTRY, 2021-2031,($MILLION)
TABLE 22. COMPUTATIONAL BIOLOGY MARKET, BY REGION, 2021-2031,($MILLION)
TABLE 23. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 24. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 25. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 26. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 27. U.S. COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 28. U.S. COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 29. U.S. COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 30. CANADA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 31. CANADA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 32. CANADA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 33. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 34. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 35. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 36. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 37. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 38. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 39. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 40. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 41. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 42. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 43. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 44. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 45. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 46. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 47. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 48. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 49. ITALY COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 50. ITALY COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 51. ITALY COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 52. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 53. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 54. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 55. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 56. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 57. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 58. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 59. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 60. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 61. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 62. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 63. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 64. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 65. CHINA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 66. CHINA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 67. CHINA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 68. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 69. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 70. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 71. INDIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 72. INDIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 73. INDIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 74. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 75. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 76. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 77. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 78. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 79. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 80. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 81. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 82. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 83. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 84. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 85. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 86. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 87. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 88. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 89. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 90. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 91. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 92. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 93. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 94. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
TABLE 95. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
TABLE 96.CHEMICAL COMPUTING GROUP INC.: COMPANY SNAPSHOT
TABLE 97.CHEMICAL COMPUTING GROUP INC.: OPERATING SEGMENTS
TABLE 98.CHEMICAL COMPUTING GROUP INC.: PRODUCT PORTFOLIO
TABLE 99.CHEMICAL COMPUTING GROUP INC.: NET SALES,
TABLE 100.CHEMICAL COMPUTING GROUP INC.: KEY STRATERGIES
TABLE 101.COMPUGEN LTD.: COMPANY SNAPSHOT
TABLE 102.COMPUGEN LTD.: OPERATING SEGMENTS
TABLE 103.COMPUGEN LTD.: PRODUCT PORTFOLIO
TABLE 104.COMPUGEN LTD.: NET SALES,
TABLE 105.COMPUGEN LTD.: KEY STRATERGIES
TABLE 106.SIMULATION PLUS INC.: COMPANY SNAPSHOT
TABLE 107.SIMULATION PLUS INC.: OPERATING SEGMENTS
TABLE 108.SIMULATION PLUS INC.: PRODUCT PORTFOLIO
TABLE 109.SIMULATION PLUS INC.: NET SALES,
TABLE 110.SIMULATION PLUS INC.: KEY STRATERGIES
TABLE 111.GENEDATA AG: COMPANY SNAPSHOT
TABLE 112.GENEDATA AG: OPERATING SEGMENTS
TABLE 113.GENEDATA AG: PRODUCT PORTFOLIO
TABLE 114.GENEDATA AG: NET SALES,
TABLE 115.GENEDATA AG: KEY STRATERGIES
TABLE 116.CERTARA: COMPANY SNAPSHOT
TABLE 117.CERTARA: OPERATING SEGMENTS
TABLE 118.CERTARA: PRODUCT PORTFOLIO
TABLE 119.CERTARA: NET SALES,
TABLE 120.CERTARA: KEY STRATERGIES
TABLE 121.INSILICO BIOTECHNOLOGY AG: COMPANY SNAPSHOT
TABLE 122.INSILICO BIOTECHNOLOGY AG: OPERATING SEGMENTS
TABLE 123.INSILICO BIOTECHNOLOGY AG: PRODUCT PORTFOLIO
TABLE 124.INSILICO BIOTECHNOLOGY AG: NET SALES,
TABLE 125.INSILICO BIOTECHNOLOGY AG: KEY STRATERGIES
TABLE 126.ACCELRYS: COMPANY SNAPSHOT
TABLE 127.ACCELRYS: OPERATING SEGMENTS
TABLE 128.ACCELRYS: PRODUCT PORTFOLIO
TABLE 129.ACCELRYS: NET SALES,
TABLE 130.ACCELRYS: KEY STRATERGIES
TABLE 131.RHENOVIA PHARMA SAS: COMPANY SNAPSHOT
TABLE 132.RHENOVIA PHARMA SAS: OPERATING SEGMENTS
TABLE 133.RHENOVIA PHARMA SAS: PRODUCT PORTFOLIO
TABLE 134.RHENOVIA PHARMA SAS: NET SALES,
TABLE 135.RHENOVIA PHARMA SAS: KEY STRATERGIES
TABLE 136.ENTELOS: COMPANY SNAPSHOT
TABLE 137.ENTELOS: OPERATING SEGMENTS
TABLE 138.ENTELOS: PRODUCT PORTFOLIO
TABLE 139.ENTELOS: NET SALES,
TABLE 140.ENTELOS: KEY STRATERGIES
TABLE 141.NIMBUS DISCOVERY LLC: COMPANY SNAPSHOT
TABLE 142.NIMBUS DISCOVERY LLC: OPERATING SEGMENTS
TABLE 143.NIMBUS DISCOVERY LLC: PRODUCT PORTFOLIO
TABLE 144.NIMBUS DISCOVERY LLC: NET SALES,
TABLE 145.NIMBUS DISCOVERY LLC: KEY STRATERGIES
TABLE 146.RHENOVIA PHARMA SAS & LEADSCOPE INC.: COMPANY SNAPSHOT
TABLE 147.RHENOVIA PHARMA SAS & LEADSCOPE INC.: OPERATING SEGMENTS
TABLE 148.RHENOVIA PHARMA SAS & LEADSCOPE INC.: PRODUCT PORTFOLIO
TABLE 149.RHENOVIA PHARMA SAS & LEADSCOPE INC.: NET SALES,
TABLE 150.RHENOVIA PHARMA SAS & LEADSCOPE INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.COMPUTATIONAL BIOLOGY MARKET SEGMENTATION
FIGURE 2.COMPUTATIONAL BIOLOGY MARKET,2021-2031
FIGURE 3.COMPUTATIONAL BIOLOGY MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.COMPUTATIONAL BIOLOGY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.COMPUTATIONAL BIOLOGY MARKET,BY APPLICATION,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CELLULAR & BIOLOGICAL SIMULATION COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DRUG DISCOVERY & DISEASE MODELLING COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PRECLINICAL DRUG DEVELOPMENT COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIALS COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HUMAN BODY SIMULATION SOFTWARE COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 18.COMPUTATIONAL BIOLOGY MARKET,BY SERVICES,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF IN-HOUSE COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CONTRACT COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 21.COMPUTATIONAL BIOLOGY MARKET,BY END USE,2021(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ACADEMICS & RESEARCH COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COMMERCIAL COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
FIGURE 24.COMPUTATIONAL BIOLOGY MARKET BY REGION,2021
FIGURE 25.U.S. COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 26.CANADA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 27.MEXICO COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 28.GERMANY COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 29.FRANCE COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 30.UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 31.ITALY COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 32.SPAIN COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 33.REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 34.JAPAN COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 35.CHINA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 36.AUSTRALIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 37.INDIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 38.SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 39.REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 40.BRAZIL COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 41.SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 42.SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 43.REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 48.COMPETITIVE DASHBOARD
FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 50.CHEMICAL COMPUTING GROUP INC..: NET SALES ,($MILLION)
FIGURE 51.COMPUGEN LTD..: NET SALES ,($MILLION)
FIGURE 52.SIMULATION PLUS INC..: NET SALES ,($MILLION)
FIGURE 53.GENEDATA AG.: NET SALES ,($MILLION)
FIGURE 54.CERTARA.: NET SALES ,($MILLION)
FIGURE 55.INSILICO BIOTECHNOLOGY AG.: NET SALES ,($MILLION)
FIGURE 56.ACCELRYS.: NET SALES ,($MILLION)
FIGURE 57.RHENOVIA PHARMA SAS.: NET SALES ,($MILLION)
FIGURE 58.ENTELOS.: NET SALES ,($MILLION)
FIGURE 59.NIMBUS DISCOVERY LLC.: NET SALES ,($MILLION)
FIGURE 60.RHENOVIA PHARMA SAS & LEADSCOPE INC..: NET SALES ,($MILLION)

Product Code: A11921

The global computational biology market was valued at $5,493.2 million in 2021, and is projected to reach $31,477.1 million by 2031, registering a CAGR of 19.5% from 2022 to 2031.

Computational biology is the inter-disciplinary applied science, which utilizes concepts of basic biology through the use of mathematical, theoretical, and computer simulation models to study biological systems, structures, and processes of life.. It entails the use of computational methods (e.g., algorithms) for the representation and simulation of biological systems as well as for the interpretation of experimental data, often on a very large scale.

The sequence and structural similarities of an unknown and a known protein as well as the proteins' interactions with other molecules are used to make functional predictions. As such analyses can be lengthy, the demand for computational biology has increased rapidly., Therefore, these analyses guide the process of building 3D models of the target protein structure, which are then refined, ranked, and compared with one another to select the final predictions.. Biochemical, regulatory, and genetic pathways are highly branched and interleaved, as well as dynamic, necessitating the use of advanced computational methods to model and analyze them.

The COVID-19 pandemic has had an impact on the computational biology market. To curb the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.

Furthermore, the outbreak of COVID-19 led to high mortality, high contagion rate, and a lack of clinically approved drugs and vaccines. To find safe and effective therapeutic options to treat this infectious disease, computational biology plays an extremely relevant role to better understand the virus pathogenic mechanism as well as to propose novel therapeutic strategies. Accordingly, due to progress in computer science, in silico methodologies in medicinal chemistry, pharmacology, biology, genetics, and virology cover relevant tasks in modern research in these fields. Furthermore, due to the current global health warning, such computational techniques could speed up research to provide innovative and targeted approaches to fight the coronavirus emergency. Hence, computational biology will help the medical science field irreversibly to find a cure and boost the growth of the pharma market.

The growth of the global computational biology market is majorly driven by rise in demand for tools of computational biology in various fields such as genomics, epi-genomics, proteomics, and meta-genomics for better understanding of protein structure and interactions.. In addition, factors fueling the market growth include rise in R&D activities for drug discovery, surge in demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding.

The application of sophisticated algorithms and statistical models in computational biology to analyze biological data enables researchers to gather critical insights, which can be utilized for discovery of new drugs. Moreover, application of machine learning and artificial intelligence allowed researchers to develop a better understanding of biological systems, discovering new drugs, designing new proteins to cure diseases, and help in understanding genetic code to predict diseases. Several start-ups in computational biology provide software platform that contributes to the pharmaceutical development process. This is expected to contribute to revenue growth of the market.

Moreover, increase in demand from the contract research organization for computational biology drives the growth of the market. Contract research organization service providers work with clients to develop a customized plan as per the requirements. For instance, the Bioinformatics CRO, Inc. is a contract research organization that offers bioinformatics services to biotechnology companies worldwide.

The computational biology software/tools help in building custom analytical pipelines to generate more critical insights from data also it can be used to further analyze gene expression data from bulk and single-cell RNA-sequence, and perform network analysis such as Weighted Gene Co-expression Network Analysis (WGCNA). Various sectors such as the pharmaceutical, biotechnology, and medical device use computational biology for developing their products. Thus, rapid development of these sectors notably contributes toward the growth of the global computational biology market.

However, complications such as allergic reactions that cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, high initial cost & maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce act as the key deterrent factors of the global market.

The global computational biology market is segmented into application, service, and end use, and region. By application, the market is segregated into cellular & biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials, and human body simulation software.

The cellular & biological simulation is sub-segmented into computer, genomics, computational proteomics, pharmacogenomics, and others. The drug discovery & disease modeling segregated into target identification, target validation, lead discovery, and lead optimization. The pre-clinical drug development segmented into pharmacokinetics and pharmacodynamics. The clinical trials are subcategorized into phase I, phase II, and phase III.

On the basis of services, the segment is divided into in-house services and contract. On the basis of end use the segment is divided into academics & research and commercials. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies that operate in the computational biology market are Altaris Capital Partner, Compugen Ltd., Certara, Genedata AG, Dassault Systems, DNAnexus, Nimbus Discovery, Instem, Rosa & Co. Ltd, and Simulation Plus.

Key Benefits For Stakeholders

This report entails a detailed quantitative analysis along with the current computational biology market trends from 2022 to 2031 to identify the prevailing opportunities along with the strategic assessment.

The computational biology market forecast is studied from 2022 to 2031.

The market size and estimations are based on a comprehensive analysis of key developments in the computational biology industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the computational biology market.

Key Market Segments

By Application

Cellular Biological Simulation
Drug Discovery Disease Modelling
Preclinical Drug Development
Clinical Trials
Human Body Simulation Software

By Services

Contract
In-house

By End Use

Academics Research
Commercial

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Chemical Computing Group Inc.
- Compugen Ltd.
- Simulation Plus Inc.
- Genedata AG
- Certara
- Insilico Biotechnology AG
- Accelrys
- Rhenovia Pharma SAS
- Entelos
- Nimbus Discovery LLC
- Rhenovia Pharma SAS & Leadscope Inc.

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Cellular & Biological Simulation
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Drug Discovery & Disease Modelling
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Preclinical Drug Development
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Clinical Trials
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
4.6 Human Body Simulation Software
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country

CHAPTER 5: COMPUTATIONAL BIOLOGY MARKET, BY SERVICES

5.1 Overview
- 5.1.1 Market size and forecast
5.2 In-house
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Contract
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: COMPUTATIONAL BIOLOGY MARKET, BY END USE

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Academics & Research
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Commercial
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country

CHAPTER 7: COMPUTATIONAL BIOLOGY MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Application
- 7.2.3 North America Market size and forecast, by Services
- 7.2.4 North America Market size and forecast, by End Use
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Application
  - 7.2.5.1.2 Market size and forecast, by Services
  - 7.2.5.1.3 Market size and forecast, by End Use
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Application
  - 7.2.5.2.2 Market size and forecast, by Services
  - 7.2.5.2.3 Market size and forecast, by End Use
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Application
  - 7.2.5.3.2 Market size and forecast, by Services
  - 7.2.5.3.3 Market size and forecast, by End Use
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Application
- 7.3.3 Europe Market size and forecast, by Services
- 7.3.4 Europe Market size and forecast, by End Use
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Application
  - 7.3.5.1.2 Market size and forecast, by Services
  - 7.3.5.1.3 Market size and forecast, by End Use
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Application
  - 7.3.5.2.2 Market size and forecast, by Services
  - 7.3.5.2.3 Market size and forecast, by End Use
  - 7.3.5.3 United Kingdom
  - 7.3.5.3.1 Market size and forecast, by Application
  - 7.3.5.3.2 Market size and forecast, by Services
  - 7.3.5.3.3 Market size and forecast, by End Use
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Application
  - 7.3.5.4.2 Market size and forecast, by Services
  - 7.3.5.4.3 Market size and forecast, by End Use
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Application
  - 7.3.5.5.2 Market size and forecast, by Services
  - 7.3.5.5.3 Market size and forecast, by End Use
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Application
  - 7.3.5.6.2 Market size and forecast, by Services
  - 7.3.5.6.3 Market size and forecast, by End Use
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Application
- 7.4.3 Asia-Pacific Market size and forecast, by Services
- 7.4.4 Asia-Pacific Market size and forecast, by End Use
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Application
  - 7.4.5.1.2 Market size and forecast, by Services
  - 7.4.5.1.3 Market size and forecast, by End Use
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Application
  - 7.4.5.2.2 Market size and forecast, by Services
  - 7.4.5.2.3 Market size and forecast, by End Use
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Application
  - 7.4.5.3.2 Market size and forecast, by Services
  - 7.4.5.3.3 Market size and forecast, by End Use
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Application
  - 7.4.5.4.2 Market size and forecast, by Services
  - 7.4.5.4.3 Market size and forecast, by End Use
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Application
  - 7.4.5.5.2 Market size and forecast, by Services
  - 7.4.5.5.3 Market size and forecast, by End Use
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Application
  - 7.4.5.6.2 Market size and forecast, by Services
  - 7.4.5.6.3 Market size and forecast, by End Use
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Application
- 7.5.3 LAMEA Market size and forecast, by Services
- 7.5.4 LAMEA Market size and forecast, by End Use
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Application
  - 7.5.5.1.2 Market size and forecast, by Services
  - 7.5.5.1.3 Market size and forecast, by End Use
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Application
  - 7.5.5.2.2 Market size and forecast, by Services
  - 7.5.5.2.3 Market size and forecast, by End Use
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Application
  - 7.5.5.3.2 Market size and forecast, by Services
  - 7.5.5.3.3 Market size and forecast, by End Use
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Application
  - 7.5.5.4.2 Market size and forecast, by Services
  - 7.5.5.4.3 Market size and forecast, by End Use

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Chemical Computing Group Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Compugen Ltd.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Simulation Plus Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Genedata AG
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Certara
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Insilico Biotechnology AG
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Accelrys
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Rhenovia Pharma SAS
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Entelos
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Nimbus Discovery LLC
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Rhenovia Pharma SAS & Leadscope Inc.
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments

計算生物学市場：用途別、サービス別、最終用途別：世界の機会分析および産業予測、2021-2031年

Computational Biology Market By Application, By Services, By End Use : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章計算生物学市場：応用分野別

第5章計算生物学市場：サービス別

第6章計算生物学市場：エンドユーザー別

第7章計算生物学市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION

CHAPTER 5: COMPUTATIONAL BIOLOGY MARKET, BY SERVICES

CHAPTER 6: COMPUTATIONAL BIOLOGY MARKET, BY END USE

CHAPTER 7: COMPUTATIONAL BIOLOGY MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

計算生物学市場：用途別、サービス別、最終用途別：世界の機会分析および産業予測、2021-2031年

Computational Biology Market By Application, By Services, By End Use : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 計算生物学市場：応用分野別

第5章 計算生物学市場：サービス別

第6章 計算生物学市場：エンドユーザー別

第7章 計算生物学市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION

CHAPTER 5: COMPUTATIONAL BIOLOGY MARKET, BY SERVICES

CHAPTER 6: COMPUTATIONAL BIOLOGY MARKET, BY END USE

CHAPTER 7: COMPUTATIONAL BIOLOGY MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章計算生物学市場：応用分野別

第5章計算生物学市場：サービス別

第6章計算生物学市場：エンドユーザー別

第7章計算生物学市場：地域別

第8章企業情勢

第9章企業プロファイル